An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

NCT04305795 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head-and-neck Squamous-cell Carcinoma
Locally Advanced Cutaneous Squamous Cell Carcinoma
Metastatic Cutaneous Squamous Cell Carcinoma

Interventions

BIOLOGICAL: 200 mg Pembrolizumab
BIOLOGICAL: 350 mg Cemiplimab
COMBINATION_PRODUCT: ASP-1929 PIT

Sponsor

Rakuten Medical, Inc.